SCHEMBL496789

SCHEMBL496789

CC(C)CCNC(=O)c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.81
NPC1 O15118 4/20 0.81
RAB9A P51151 4/20 0.81
EPHX2 P34913 2/20 0.69
KCNA5 P22460 1/20 0.66
LMNA P02545 2/20 0.61
POLB P06746 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.58
NAAA Q02083 1/20 0.57
NAMPT P43490 1/20 0.57
GRM5 P41594 1/20 0.57
GAA P10253 1/20 0.57
HTT P42858 1/20 0.55
PRSS1 P07477 1/20 0.54
CTSG P08311 1/20 0.54
CTRB1 P17538 1/20 0.54
CMA1 P23946 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17225741 0.93 SMN1; SMN2 (0.77) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL17887994 0.90 SMN1; SMN2 (0.77) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL1927508 0.90 NPC1 (1.00) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL10137831 0.89 SMN1; SMN2 (0.67) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL12650598 0.88 NAAA (0.66) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL10099547 0.86 NAAA (0.69) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL1927498 0.86 SMN1; SMN2 (0.76) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL3638357 0.86 GRM5 (0.73) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL8851563 0.86 EPHX2 (0.65) SMN1; SMN2NPC1RAB9AEPHX2KCNA5
SCHEMBL27389698 0.86 EPHX2 (0.65) SMN1; SMN2NPC1RAB9AEPHX2KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3911645-B1 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE UNIV LILLE (FR) 2022-12-07 EP claimed
WO-2008093064-A1 L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS ASTRAZENECA AB (SE) 2008-08-07 WO claimed
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ASTRAZENECA AB (SE) 2008-07-31 US claimed
EP-1497261-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-01-19 EP claimed
WO-2003091204-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-11-06 WO claimed
WO-2003047572-A1 USE OF 1-PHENYL-OXAZOLIDINE-2-ONE COMPOUNDS AS PROTEASE M INHIBITORS MERCK PATENT GMBH (DE) 2003-06-12 WO claimed
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION FIRMENICH & CIE (CH) 2026-03-12 US disclosed
CN-119504643-A 3- (2-Aminobenzo [ d ] thiazol-5-yl) benzamide derivative and preparation method and application thereof 贵州省天然产物研究中心 2025-02-25 CN disclosed
CN-118480001-A C-Kit (V559D)/PDGFR beta double-target allosteric inhibitor and preparation method, pharmaceutical composition and application thereof 贵州省天然产物研究中心 2024-08-13 CN disclosed
CN-113873884-B Arthropod control composition 弗门尼舍有限公司 2024-06-14 CN disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
CN-116253686-B Aminobenzimidazole benzamide derivative and application thereof 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2023-11-17 CN disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ASTRAZENECA AB (SE) 2008-07-31 US disclosed
EP-1701956-A1 PYRROLO[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pfizer Italia S.r.l. (IT) 2006-09-20 EP disclosed
CN-1753670-A Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments SOD CONSEILS RECH APPLIC (FR) 2006-03-29 CN disclosed
US-20050256151-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-11-17 US disclosed
WO-2005063746-A1 PYRROLO[2,3-b]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA S.R.L. (IT) 2005-07-14 WO disclosed
EP-1497261-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-01-19 EP disclosed
WO-2003091204-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION CNOT9, MSL1, MT-CO2 SMN1; SMN2 2293/4885NPC1 1270/4885RAB9A 77/4885
US-20050256151-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K6, MAP3K3, MAP3K1 SMN1; SMN2 1459/4885NPC1 3315/4885RAB9A 1269/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS SMN1; SMN2 2633/4885NPC1 667/4885RAB9A 2346/4885
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ITGB1, ITGA2B, ITGB5 SMN1; SMN2 1605/4885NPC1 3892/4885RAB9A 1382/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS SMN1; SMN2 2633/4885NPC1 667/4885RAB9A 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.